We are live on
!
Find out more
E Fund Management Portfolio holdings
AUM
$4.46B
Turnover
13.19%
This Fund
S&P 500
This Quarter
Est. Return
+29.65%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.58B
AUM Growth
+$264M
(+20%)
Cap. Flow
-$56.9M
Cap. Flow
% of AUM
-3.61%
Top 10 Holdings %
Top 10 Hldgs %
70.28%
Holding
330
New
38
Increased
107
Reduced
155
Closed
24
Avg Time Held
1.8
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JOYY Inc
JOYY
|
+$3.5M |
| 2 |
Weibo
WB
|
+$2.7M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$1.76M |
| 4 |
Hesai Group
HSAI
|
+$1.67M |
| 5 |
Structure Therapeutics
GPCR
|
+$1.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
STAAR Surgical
STAA
|
+$23.4M |
| 2 |
Yum China
YUMC
|
+$14M |
| 3 |
TSMC
TSM
|
+$8.84M |
| 4 |
Pinduoduo
PDD
|
+$8.79M |
| 5 |
Apple
AAPL
|
+$4.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 50.26% |
| 2 | Technology | 23.48% |
| 3 | Communication Services | 8.85% |
| 4 | Real Estate | 5.2% |
| 5 | Healthcare | 4.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
DELISTED
Blueprint Medicines
BPMC
| $599K | 0.04% |
6,493
-2,072
| -24% | -$134K |
2022 Q1
7 quarters
|
|
127
Camtek
CAMT
$6.01B
| $599K | 0.04% |
+8,627
| New | +$525K |
2023 Q4
0 quarters
|
|
128
Arrowhead Research
ARWR
$7.96B
| $598K | 0.04% |
19,531
+4,238
| +28% | +$113K |
2022 Q1
7 quarters
|
|
129
BridgeBio Pharma
BBIO
$13B
| $596K | 0.04% |
14,769
-1,326
| -8% | -$39.8K |
2022 Q1
7 quarters
|
|
130
Airbnb
ABNB
$102B
| $593K | 0.04% |
4,354
-334
| -7% | -$43.1K |
2021 Q4
8 quarters
|
|
131
CRISPR Therapeutics
CRSP
$4.77B
| $592K | 0.04% |
9,460
+303
| +3% | +$16.8K |
2022 Q2
6 quarters
|
|
132
Merck
MRK
$361B
| $587K | 0.04% |
5,388
+616
| +13% | +$63.9K |
2021 Q1
11 quarters
|
|
133
Monster Beverage
MNST
$89.4B
| $574K | 0.04% |
19,920
-2,164
| -10% | -$57.8K |
2021 Q1
11 quarters
|
|
134
Ultragenyx Pharmaceutical
RARE
$1.44B
| $568K | 0.04% |
11,871
+2,467
| +26% | +$95.6K |
2022 Q1
7 quarters
|
|
135
DELISTED
Akero Therapeutics
AKRO
| $564K | 0.04% |
24,172
+14,744
| +156% | +$291K |
2022 Q4
4 quarters
|
|
136
Revolution Medicines
RVMD
$38B
| $560K | 0.04% |
19,532
+7,877
| +68% | +$189K |
2022 Q2
6 quarters
|
|
137
O'Reilly Automotive
ORLY
$71.9B
| $560K | 0.04% |
8,835
-1,125
| -11% | -$71.1K |
2021 Q1
11 quarters
|
|
138
Krystal Biotech
KRYS
$9.43B
| $558K | 0.04% |
4,495
+808
| +22% | +$89.6K |
2022 Q1
7 quarters
|
|
139
DELISTED
Exact Sciences
EXAS
| $549K | 0.03% |
7,421
+1,583
| +27% | +$104K |
2022 Q1
7 quarters
|
|
140
Roivant Sciences
ROIV
$24.2B
| $549K | 0.03% |
48,860
+12,569
| +35% | +$122K |
2022 Q4
4 quarters
|
|
141
Charter Communications
CHTR
$12.6B
| $548K | 0.03% |
1,409
-163
| -10% | -$66.5K |
2021 Q1
11 quarters
|
|
142
Home Depot
HD
$308B
| $547K | 0.03% |
1,577
+8
| +0.5% | +$2.48K |
2021 Q1
11 quarters
|
|
143
Baidu
BIDU
$27.3B
| $545K | 0.03% |
4,578
| – | – |
2023 Q3
1 quarter
|
|
144
Procter & Gamble
PG
$369B
| $544K | 0.03% |
3,715
+36
| +1% | +$5.33K |
2021 Q1
11 quarters
|
|
145
Iovance Biotherapeutics
IOVA
$6.21B
| $543K | 0.03% |
66,738
-10,112
| -13% | -$52.9K |
2022 Q1
7 quarters
|
|
146
DELISTED
Ansys
ANSS
| $540K | 0.03% |
1,489
-119
| -7% | -$35.2K |
2021 Q1
11 quarters
|
|
147
Neurocrine Biosciences
NBIX
$13.8B
| $540K | 0.03% |
4,096
-89
| -2% | -$10.2K |
2022 Q1
7 quarters
|
|
148
Madrigal Pharmaceuticals
MDGL
$10.5B
| $534K | 0.03% |
2,306
-21
| -0.9% | -$3.67K |
2022 Q1
7 quarters
|
|
149
Recursion Pharmaceuticals
RXRX
$1.87B
| $533K | 0.03% |
54,094
-2,638
| -5% | -$18.8K |
2022 Q3
5 quarters
|
|
150
Insmed
INSM
$21.2B
| $532K | 0.03% |
17,178
+3,130
| +22% | +$81.2K |
2022 Q1
7 quarters
|
|
Similar funds
E Fund Management's Q4 2023 Portfolio in Review
As of Q4 2023, E Fund Management held 330 positions worth $1.58B, up 20% from $1.31B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
E Fund Management withdrew a net $56.9M in Q4 2023, closing 24 positions and reducing 155 holdings. Its most notable exit was MINISO, an estimated $2.17M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 50% of assets, up from 45% a quarter earlier, followed by Technology and Communication Services.
Against the trend, E Fund Management opened a new position in Hesai Group worth $1.52M.
- E Fund Management's largest Q4 2023 buy was Hesai Group: 170,914 shares worth $1.52M.
- E Fund Management added most to JOYY Inc in Q4 2023, an estimated $3.5M increase.
- E Fund Management's biggest Q4 2023 reduction was STAAR Surgical, cutting an estimated $23.4M.
- E Fund Management fully exited MINISO in Q4 2023, selling an estimated $2.17M.
- E Fund Management's ten largest holdings make up 70% of its $1.58B portfolio in Q4 2023.
- E Fund Management opened 38 new positions and closed 24 in Q4 2023.
- E Fund Management's portfolio value rose 20% quarter-over-quarter to $1.58B.
Based on E Fund Management's 13F filing for Q4 2023, filed 7 Feb 2024.